Physician profile
John Dzik
NPI 1659346948
$2,294.52
in general payments reported to CMS, 2019-2025
23 companies · $619 in 2025
The $619 reported for 2025 was more than what 95% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $91.11 · 2021: $315 · 2022: $329 · 2023: $411 · 2024: $313 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $575.10 | 2019-2025 | Bexsero, Penmenvy |
| Merck Sharp & Dohme LLC | $499.74 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Pfizer INC. | $215.70 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.53 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $130.18 | 2025 | Kristalose |
| Alk-Abello, INC | $118.40 | 2023-2025 | Ragwitek, Odactra, Grastek |
| Sanofi-Aventis U.S. LLC | $95.03 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $92.93 | 2019-2023 | Jornay Pm |
| Seqirus USA INC | $81.32 | 2022-2025 | Flucelvax |
| Sanofi Pasteur INC. | $65.37 | 2019-2023 | |
| Cranial Technologies, INC | $51.38 | 2024-2025 | Doc Band |
| Corium, LLC | $33.64 | 2022-2025 | Azstarys |
| Tris Pharma INC | $20.89 | 2022 | |
| Fennec Pharmaceuticals, INC. | $20.27 | 2023 | Pedmark |
| Vertical Pharmaceuticals, LLC | $19.69 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $19.52 | 2025 | Spinosad, Natroba |
| Supernus Pharmaceuticals, INC. | $16.70 | 2022 | |
| Neos Therapeutics, LP | $16.70 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $16.00 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $15.42 | 2022 | |
| Kaleo, INC. | $15.39 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.71 | 2023 | Flumist Quadrivalent |
| Shire North American Group INC | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dzik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.